|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1994-6-23
|
|
pubmed:abstractText |
Due to the possibility of a synergistic effect between Interferon (IFN-alpha) and 5-fluorouracil (5-FU), a phase II trial was conducted in metastatic renal cell carcinoma (MRCC) combining recombinant IFN-alpha, 5-FU and prednisone. Prednisone has been shown to decrease IFN-alpha-related toxicity without reducing the response rate.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
245-8
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8186172-Adolescent,
pubmed-meshheading:8186172-Adult,
pubmed-meshheading:8186172-Aged,
pubmed-meshheading:8186172-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8186172-Carcinoma, Renal Cell,
pubmed-meshheading:8186172-Drug Administration Schedule,
pubmed-meshheading:8186172-Female,
pubmed-meshheading:8186172-Fluorouracil,
pubmed-meshheading:8186172-Humans,
pubmed-meshheading:8186172-Interferon-alpha,
pubmed-meshheading:8186172-Kidney Neoplasms,
pubmed-meshheading:8186172-Male,
pubmed-meshheading:8186172-Middle Aged,
pubmed-meshheading:8186172-Prednisone,
pubmed-meshheading:8186172-Treatment Outcome
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study.
|
|
pubmed:affiliation |
Department of Oncology, Regional Hospital Trondheim, Norway.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
